Kenneth E Draper

US Patent:

55917208, Jan 7, 1997

Filed:

Nov 19, 1992

Appl. No.:

7/927506

Inventors:

Kevin P. Anderson - Carlsbad CA
Kenneth G. Draper - Richmond OH

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 3170
G07H 2104

US Classification:

514 44

Abstract:

Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide or oligonucleotide analog which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides or oligonucleotide analogs are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed.

US Patent:

63100444, Oct 30, 2001

Filed:

Apr 28, 1992

Appl. No.:

7/852132

Inventors:

Kenneth G. Draper - San Marcos CA
David J. Ecker - Carlsbad CA
Christopher K. Mirabelli - Encinitas CA
Stanley T. Crooke - Carlsbad CA

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 4800
C07H 2104
C12Q 168
C12P 1934

US Classification:

514 44

Abstract:

Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

US Patent:

52486702, Sep 28, 1993

Filed:

Feb 26, 1990

Appl. No.:

7/485297

Inventors:

Kenneth G. Draper - San Marcos CA
David J. Ecker - Carlsbad CA
Christopher K. Mirabelli - Encinitas CA
Stanley T. Crooke - Carlsbad CA

Assignee:

ISIS Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 3170
C07H 2100
C07H 2102
C07H 2104

US Classification:

514 44

Abstract:

Antisense oligonucleotides are disclosed having a length of 15-30 nucleotides containing the CAT sequence and hybridizable to herpes simplex virus type I gene UL13, UL39, or UL40. These antisense oligomers inhibit the replication of the virus at least three-fold. Pharmaceutical compositions containing these oligonucleotides as the active ingredients are also disclosed.

US Patent:

54420490, Aug 15, 1995

Filed:

Jan 25, 1993

Appl. No.:

8/009263

Inventors:

Kevin Anderson - Carlsbad CA
Kenneth Draper - Boulder CO
Brenda Baker - Encinitas CA

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C07H 2104
A61K 4800

US Classification:

536 245

Abstract:

Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides such as ISIS 2922 are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed.

US Patent:

56588917, Aug 19, 1997

Filed:

Oct 26, 1994

Appl. No.:

8/329212

Inventors:

Kenneth G. Draper - San Marcos CA
David J. Ecker - Carlsbad CA
Christopher K. Mirabelli - Encinitas CA
Stanley T. Crooke - Carlsbad CA

Assignee:

Isis Pharmaceuticals, Inc.

International Classification:

A61K 3170
C07H 2100
C12N 510
C12Q 168

US Classification:

514 44

Abstract:

Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus; are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.